stage ivc squamous cell carcinoma of the larynx

Showing 1 - 15 of 15

STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS

Recurrent Adenoid Cystic Carcinoma of the Oral Cavity, Recurrent Mucoepidermoid Carcinoma of the Oral Cavity, Recurrent Squamous

Recruiting
  • Recurrent Adenoid Cystic Carcinoma of the Oral Cavity
  • +50 more
  • transoral robotic surgery
  • quality of life assessment
  • Columbus, Ohio
    Ohio State University Medical Center
Oct 28, 2022

Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma, Recurrent Metastatic Squamous Neck Cancer With

Completed
  • Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma
  • +35 more
  • PI3K inhibitor BKM120
  • cetuximab
  • Chicago, Illinois
    University of Chicago Comprehensive Cancer Center
Sep 14, 2021

Stage IV Head and Neck Cancer or Stage III-IV Non-small Cell

Active, not recruiting
  • Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma
  • +29 more
  • Cytology specimen
  • Laboratory biomarker analysis
  • Philadelphia, Pennsylvania
    Thomas Jefferson University
Aug 31, 2021

Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma, Salivary Gland Squamous Cell Carcinoma, Stage 0

Completed
  • Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma
  • +57 more
  • placebo
  • +3 more
  • Columbus, Ohio
    Ohio State University Medical Center
Feb 18, 2020

Human Papilloma Virus Infection, Stage III Squamous Cell Carcinoma of the Hypopharynx, Stage III Squamous Cell Carcinoma of the

Completed
  • Human Papilloma Virus Infection
  • +15 more
  • Los Angeles, California
    Jonsson Comprehensive Cancer Center
Aug 10, 2018

Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma, Recurrent Metastatic Squamous Neck Cancer With

Completed
  • Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma
  • +36 more
  • sorafenib tosylate
  • +3 more
  • Columbus, Ohio
    Arthur G. James Cancer Hospital and Solove Research Institute at
May 22, 2018

Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma, Recurrent Metastatic Squamous Neck Cancer With

Terminated
  • Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma
  • +45 more
  • talactoferrin
  • laboratory biomarker analysis
  • Stanford, California
    Stanford University
Jul 30, 2016

Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma, Recurrent Metastatic Squamous Neck Cancer With

Completed
  • Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma
  • +35 more
  • Houston, Texas
    M D Anderson Cancer Center
Sep 17, 2014

Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma, Stage III Squamous Cell Carcinoma of the

Completed
  • Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma
  • +26 more
  • erlotinib hydrochloride
  • +5 more
  • Cleveland, Ohio
    Case Western Reserve University
Jun 5, 2014

Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma, Recurrent Metastatic Squamous Neck Cancer With

Completed
  • Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma
  • +38 more
  • New York, New York
    Memorial Sloan Kettering Cancer Center
Apr 2, 2014

Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma, Recurrent Metastatic Squamous Neck Cancer With

Completed
  • Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma
  • +33 more
  • Boston, Massachusetts
    Eastern Cooperative Oncology Group
Feb 26, 2013

Anaplastic Thyroid Cancer, Insular Thyroid Cancer, Metastatic Parathyroid Cancer Trial in San Antonio (gefitinib)

Completed
  • Anaplastic Thyroid Cancer
  • +85 more
  • San Antonio, Texas
    Southwest Oncology Group
Jan 11, 2013

Recurrent NSCLC, Recurrent Ovarian Epithelial Cancer, Recurrent Squamous Cell Carcinoma of the Hypopharynx Trial in Chicago

Completed
  • Recurrent Non-small Cell Lung Cancer
  • +29 more
  • erlotinib hydrochloride
  • +3 more
  • Chicago, Illinois
    University of Chicago Comprehensive Cancer Center
Jan 8, 2013